However, the primary cells from CML patients treated with Imatinib or dasatinib, in whom the level of BCR/ABL gene expression was very low or negative, were resistant to JNJ-165, the TKIs, and combination therapy with JNJ-165 and either TKI (Figure 5I). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.